Management of Type 2 Diabetes in Patients with eGFR 40

Primary Recommendation: SGLT2 Inhibitors

The American Diabetes Association recommends SGLT2 inhibitors as the preferred first-line oral agent for patients with type 2 diabetes and eGFR ≥20 mL/min/1.73 m², with a Grade 1A recommendation 2
SGLT2 inhibitors provide cardiovascular and kidney protection benefits that extend beyond glycemic control, making them superior to other oral agents in this population 2
Once initiated, SGLT2 inhibitors can be continued even if eGFR falls below 20 mL/min/1.73 m² for ongoing kidney and cardiovascular protection 2, 3
The Kidney International journal suggests temporarily withholding SGLT2 inhibitors during prolonged fasting, surgery, or critical illness due to ketosis risk 2

The American College of Clinical Endocrinologists recommends linagliptin as the optimal DPP-4 inhibitor choice as it requires no dose adjustment regardless of kidney function 1
Other DPP-4 inhibitors (sitagliptin, saxagliptin, alogliptin) require dose reduction based on eGFR and are less convenient 1
DPP-4 inhibitors have intermediate glucose-lowering efficacy, are weight-neutral, and carry no hypoglycemia risk when used as monotherapy 1

Glyburide is absolutely contraindicated in any degree of CKD, according to the American Diabetes Association 1, 4, 5
Second-generation sulfonylureas (glipizide, glimepiride) can be used but must be initiated conservatively with close monitoring due to hypoglycemia risk 1
Sulfonylureas cause weight gain, have high hypoglycemia risk, and provide no cardiovascular or renal protection 1

The clinical algorithm suggests starting with an SGLT2 inhibitor (dapagliflozin, empagliflozin, or canagliflozin) for combined glycemic, cardiovascular, and renal benefits 2
If SGLT2 inhibitor is contraindicated or not tolerated, start linagliptin (no dose adjustment needed) 1

The National Kidney Foundation recommends checking eGFR every 3-6 months at minimum in CKD stage 3b 3
Monitor serum potassium within 2-4 weeks if starting or adjusting RAAS inhibitors concurrently 2
HbA1c remains reliable for glycemic monitoring at eGFR 40 (accuracy maintained down to eGFR 30) 6
Target HbA1c should be individualized between <6.5% to <8.0% based on hypoglycemia risk, with less stringent targets (7-8%) appropriate for those at higher risk 6, 5